Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 23, 2026.

Serologic Evidence of Severe Fever with Thrombocytopenia Syndrome Virus and Related Viruses in Pakistan

Ali Zohaib, Jingyuan Zhang, Muhammad Saqib and 23 more

Emerging Infectious Diseases · 2020

doi:10.3201/eid2607.190611

Abstract

S evere fever with thrombocytopenia syndrome (SFTS) is an emerging tickborne disease caused by the SFTS virus (SFTSV; genus Banyangvirus, family Phenuiviridae, order Bunyavirales).The disease is prevalent in East Asia countries.It was first detected in China in 2009 and later in Japan and South Korea (1) and is suspected to be widely spread across other parts of the world (2).The recent identification of SFTSV in Xinjiang, China (3), expanded our awareness of epidemic areas of SFTS and suggested the possibility of SFTSV spreading to bordering countries like Pakistan.However, the presence of SFTSV in Pakistan has been unclear.We investigated the seroprevalence of SFTSV in humans in Pakistan. The StudyFor this study, we randomly collected human serum samples (n = 1,657) from 4 provinces in Pakistan during 2016 -2017 (Figure) (Figure).All participants were farmers of livestock (sheep, goats, cattle, buffaloes, and camels).We recorded and summarized testing results by sex, age, and geographic location (Table ).The collection of human serum samples and subsequent tests were reviewed and approved by the Ethics Committees of Government College University, Faisalabad, Pakistan (approval number: GCUF/MICRO/18/1598). Adult participants and parents of participants <18 years of age provided written informed consent.We used a 2-step approach to detect antibodies against SFTSV.First, we screened the samples for SFTSV IgG by using a SFTSV human commercial ELISA kit (NZK Bio-tech, https://hbnzk.com), which employs SFTSV nucleocapsid protein (NP) as the viral antigen.To set up negative and positive controls, we used serum samples from 3 healthy persons from Wuhan, China (4), and serum samples from 2 convalescent SFTS patients from Wuhan archived in the Serologic Evidence of Severe Fever with Thrombocytopenia Syndrome Virus and Related Viruses in Pakistan

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tickborne disease caused by the SFTS virus (SFTSV; genus Banyangvirus, family Phenuiviridae, order Bunyavirales). The disease is prevalent in East Asia countries. It was first detected in China in 2009 and later in Japan and South Korea and is suspected to be widely spread across other parts of the world. The recent identification of SFTSV in Xinjiang, China, expanded our awareness of epidemic areas of SFTS and suggested the possibility of SFTSV spreading to bordering countries like Pakistan. However, the presence of SFTSV in Pakistan has been unclear. We investigated the seroprevalence of SFTSV in humans in Pakistan.

The Study

For this study, we randomly collected human serum samples (n = 1,657) from 4 provinces in Pakistan during 2016–2017 (Figure). All participants were farmers of livestock (sheep, goats, cattle, buffaloes, and camels). We recorded and summarized testing results by sex, age, and geographic location (Table). The collection of human serum samples and subsequent tests were reviewed and approved by the Ethics Committees of Government College University, Faisalabad, Pakistan (approval number: GCUF/MICRO/18/1598). Adult participants and parents of participants <18 years of age provided written informed consent.

We used a 2-step approach to detect antibodies against SFTSV. First, we screened the samples for SFTSV IgG by using a SFTSV human commercial ELISA kit (NZK Bio-tech, https://hbnzk.com), which employs SFTSV nucleocapsid protein (NP) as the viral antigen. To set up negative and positive controls, we used serum samples from 3 healthy persons from Wuhan, China, and serum samples from 2 convalescent SFTS patients from Wuhan archived in the National Virus Resource Center (accession nos. YB17WIVS286, YB17WIVS294). Following manufacturer instructions (Appendix), we tested serum samples at 1:20 dilution; we considered samples IgG-positive when the absorbance was >2.1 times the mean absorbance of the negative control. Samples with optical density values >0.41 were considered SFTSV IgG–positive (Appendix Figure 1). We used an immunofluorescence assay modified from a previous study to verify the validity of the commercial ELISA.

In the second step, we used a microneutralization test (MNT) assay to distinguish SFTSV-specific neutralizing antibodies from SFTSV-related viruses, as described elsewhere; we estimated SFTSV prevalence from ELISA and MNT results within 95% CIs. We performed statistical analysis of the data using the χ2 test or Fisher exact test to explore the association of SFTSV with age, sex, and location. We performed the analysis in R version 3.5.1 with the Epicalc package version 2.15.1.0 (http://www.r-project.org).

The ELISA revealed a high seroprevalence (46.7%, 95% CI 44.3%–49.1%) of SFTSV in Pakistan (Table; Figure). Spatial distribution analysis indicated the highest prevalence (51.8%, 95% CI 48.4%–55.2%) in the Punjab province, followed by Balochistan (47.5%, 95% CI 40.1%–55.1%), Sindh (40.5%, 95% CI 36.3%–44.9%), and Khyber Pakhtunkhwa (32.6%, 95% CI 23.2%–43.2%). The prevalence was significantly higher (p = 0.004) in women (49. 9%, 95% CI 46.6%–53.2%) than in men (42.7%, 95% CI 39.1%–46.4%). The seroprevalence increased with age, but not uniformly; the highest seroprevalence (57.1%, 95% CI 28.9%–82.3%) was recorded in samples from persons >65 years of age. A technician unaware of the ELISA results and research details performed a single-blind test with 90 ELISA-negative and 252 ELISA-positive samples, randomly selected. This test confirmed results for 100% of the ELISA-negative samples and 212 (84.1%) of 252 of the ELISA-positive samples (Appendix Figure 2).

We confirmed SFTSV infection using MNT, which revealed a low prevalence (2.5%, 95% CI 1.9%–3.4%) in Pakistan (Table; Appendix Figure 3). Women had a higher occurrence of anti-SFTSV neutralizing antibodies (2.7%, 95% CI 1.8%–4.0%) than men (2.3%, 95% CI 1.4%–3.7%), however, this difference was not significant (p = 0.619). Neutralizing antibodies were detected in all age groups. Furthermore, we performed MNT for a novel virus, Guertu virus (GTV), which is closely related to SFTSV, on 10 randomly selected serum samples that tested positive for SFTSV neutralization and 10 SFTSV IgG–positive samples that were negative for neutralization (Appendix Figure 3). All 10 samples that tested negative on the SFTSV MNT also tested negative on the GTV MNT. However, 3 of the 10 samples that tested positive on the SFTSV MNT also exhibited neutralization to GTV; the other 7 samples tested negative for neutralizing GTV.

Conclusions

This study highlights the activity of SFTSV and its substantial risks to the population in Pakistan. The observed high ELISA-based prevalence could be ascribed to the study population in this survey being livestock farmers, who could be more frequently exposed to tick vectors and livestock reservoirs. Higher estimates of SFTS prevalence in the Punjab province of Pakistan could be attributed to the high proximity of human and livestock populations in this region. Higher prevalence among women than among men was expected because livestock is mostly tended by female farmers.

In ELISA-based estimates of SFTSV in the human population reported from different areas of East Asian countries, seroprevalence has ranged from 0.23% to 9.17% in China, from 1.9% to 7.7% in Korea, and from 0.14% to 0.3% in Japan. In contrast to the findings from these reports, our study found a markedly high ELISA-based prevalence of SFTSV (46.7%) in Pakistan. The use of different SFTSV antibody detection methods may have led to the observed differences in results; nevertheless, results of the blind test using an immunofluorescence assay still suggested a high prevalence, such that 84.12% of the randomly selected ELISA-positive serum samples could react with the SFTSV antigen. Therefore, the low prevalence of neutralizing antibodies (2.5%) against SFTSV suggests the possibility of cocirculating antigenicity-related viruses that were not discernable in the indirect ELISA tests.

The genus Banyangvirus currently includes the Bhanja and SFTS/Heartland groups. The 5 viruses of the SFTS/Heartland group have a wide geographic distribution. SFTSV is found mostly in China, Japan, and South Korea; GTV in northwestern China (XJUAR), Heartland virus in the United States; Hunter Island group virus in Australia; and Malsoor virus in India.

Similar to findings in our study, a high seroprevalence (19.8%) of GTV was detected among the local residents of Guertu County in Xinjiang, China; however, only 3 (0.65%) of the 465 serum samples had neutralizing antibodies against GTV. Antigenic cross-reactivity between SFTSV and GTV was suspected because cross-neutralization was observed in mouse serum. However, serologic investigation of other bunyaviruses is limited, and serotypes of the 2 viruses, as well as other related viruses in the SFTS/Heartland group, remain unclear.

Our subsequent study found that a few serum samples exhibiting neutralization to SFTSV also exhibited cross-neutralization to GTV. All of these results indicate the presence in Pakistan of SFTSV and SFTSV-related viruses that might share antigenic similarity and could induce antibodies exhibiting cross-reactivity with each other. In addition, a recent study reported suspected clinical SFTS cases in Pakistan; however, they were not confirmed using serologic or molecular tests.

Our findings suggest the potential risk for infection from SFTSV and SFTSV-related viruses in Pakistan. Further work on the discovery, identification, and ecology of these viruses in ticks, animal hosts, and human patients is needed because the viruses pose potential threats to public health.

References 15

  1. 1.

    Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014;14:763–72.

    Not in our library10.1016/s1473-3099(14)70718-2

  2. 2.

    Denic S, Janbeih J, Nair S, Conca W, Tariq WU, Al-Salam S. Acute thrombocytopenia, leucopenia, and multiorgan dysfunction: the first case of SFTS bunyavirus outside China? Case Rep Infect Dis. 2011;2011:204056.

    Not in our library10.1155/2011/204056

  3. 3.

    Zhu L, Yin F, Moming A, Zhang J, Wang B, Gao L, et al. First case of laboratory-confirmed severe fever with thrombocytopenia syndrome disease revealed the risk of SFTSV infection in Xinjiang, China. Emerg Microbes Infect. 2019;8:1122–5.

    Not in our library10.1080/22221751.2019.1645573

  4. 4.

    Shen S, Duan X, Wang B, Zhu L, Zhang Y, Zhang J, et al. A novel tick-borne phlebovirus, closely related to severe fever with thrombocytopenia syndrome virus and Heartland virus, is a potential pathogen. Emerg Microbes Infect. 2018;7:95.

    Not in our library10.1038/s41426-018-0093-2

  5. 5.

    Zhang Y, Shen S, Shi J, Su Z, Li M, Zhang W, et al. Isolation, characterization, and phylogenic analysis of three new severe fever with thrombocytopenia syndrome bunyavirus strains derived from Hubei Province, China. Virol Sin. 2017;32:89–96.

    Not in our library10.1007/s12250-017-3953-3

  6. 6.

    Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364:1523–32.

    Not in our library10.1056/nejmoa1010095

  7. 7.

    Li P, Tong ZD, Li KF, Tang A, Dai YX, Yan JB. Seroprevalence of severe fever with thrombocytopenia syndrome virus in China: A systematic review and meta-analysis. PLoS One. 2017;12:e0175592.

    Not in our library10.1371/journal.pone.0175592

  8. 8.

    Han MA, Kim CM, Kim DM, Yun NR, Park SW, Han MG, et al. Seroprevalence of severe fever with thrombocytopenia syndrome virus antibodies in rural areas, South Korea. Emerg Infect Dis. 2018;24.

    Not in our library10.3201/eid2405.152104

  9. 9.

    Kim KH, Ko MK, Kim N, Kim HH, Yi J. Seroprevalence of severe fever with thrombocytopenia syndrome in southeastern Korea, 2015. J Korean Med Sci. 2017;32:29–32.

    Not in our library10.3346/jkms.2017.32.1.29

  10. 10.

    Kimura T, Fukuma A, Shimojima M, Yamashita Y, Mizota F, Yamashita M, et al. Seroprevalence of severe fever with thrombocytopenia syndrome (SFTS) virus antibodies in humans and animals in Ehime prefecture, Japan, an endemic region of SFTS. J Infect Chemother. 2018;24:802–6.

    Not in our library10.1016/j.jiac.2018.06.007

  11. 11.

    Gokuden M, Fukushi S, Saijo M, Nakadouzono F, Iwamoto Y, Yamamoto M, et al. Low seroprevalence of severe fever with thrombocytopenia syndrome virus antibodies in individuals living in an endemic area in Japan. Jpn J Infect Dis. 2018;71:225–8.

    Not in our library10.7883/yoken.jjid.2017.497

  12. 12.

    McMullan LK, Folk SM, Kelly AJ, MacNeil A, Goldsmith CS, Metcalfe MG, et al. A new phlebovirus associated with severe febrile illness in Missouri. N Engl J Med. 2012;367:834–41.

    Not in our library10.1056/nejmoa1203378

  13. 13.

    Wang J, Selleck P, Yu M, Ha W, Rootes C, Gales R, et al. Novel phlebovirus with zoonotic potential isolated from ticks, Australia. Emerg Infect Dis. 2014;20:1040–3.

    Not in our library10.3201/eid2006.140003

  14. 14.

    Mourya DT, Yadav PD, Basu A, Shete A, Patil DY, Zawar D, et al. Malsoor virus, a novel bat phlebovirus, is closely related to severe fever with thrombocytopenia syndrome virus and heartland virus. J Virol. 2014;88:3605–9.

    Not in our library10.1128/jvi.02617-13

  15. 15.

    Mahmood N, Khurram M, Khan MM, Umar M, Jalil A, Sharif S, et al. Characteristics of probable severe fever with thrombocytopenia syndrome patients: a perspective study from Pakistan. Int J Med Dev Coun. 2019;3:272–8.

    Not in our library10.24911/ijmdc.51-1544507442

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.